Drug Profile
Cedazuridine/decitabine - Astex Pharmaceuticals
Alternative Names: ASTX-727; ASTX-727-LD; ASTX727-10; Cedazuridine/Decitabine; Decitabine/cedazuridine; Decitabine/E7727; E-7727/decitabine; Inaqovi; INQOVI; Oral C-DECLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Astex Pharmaceuticals; National Cancer Institute (USA)
- Developer Astex Pharmaceuticals; Otsuka Pharmaceutical; Taiho Oncology; Taiho Pharma Canada
- Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Fluorinated hydrocarbons; Pyrimidine nucleosides; Ribonucleosides; Small molecules; Triazines
- Mechanism of Action Antimetabolites; Cytidine deaminase inhibitors; DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Registered Acute myeloid leukaemia
- Phase I/II Myeloproliferative disorders
- Phase I Breast cancer; Glioma
- No development reported Solid tumours
Most Recent Events
- 14 Mar 2024 Pfizer completes a phase-I clinical trial in Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT04134884)
- 07 Mar 2024 M.D. Anderson Cancer Center and Astex Pharmaceuticals initiate a phase Ia/Ib trial in Acute myeloid leukemia (In children, In adolescents, Combination therapy) in USA (PO) (NCT06191978)
- 31 Dec 2023 Phase-I/II clinical trials in Myelodysplastic syndromes in China (PO), prior to December 2023 (Otsuka Pharmaceutical pipeline, February 2024)